VALLON PHARMACEUTICALS INC (VLON) Stock Price, Forecast & Analysis
NASDAQ:VLON • US92023M1018
VLON Key Statistics, Chart & Performance
The current stock price of VLON is 0.4 USD. In the past month the price decreased by -2.44%. In the past year, price decreased by -82.38%.
VLON Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VLON. When comparing the yearly performance of all stocks, VLON is a bad performer in the overall market: 76.9% of all stocks are doing better.
VLON Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VLON. Both the profitability and financial health of VLON have multiple concerns.
VLON Financial Highlights
Over the last trailing twelve months VLON reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 44.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
VLON Forecast & Estimates
7 analysts have analysed VLON and the average price target is 12.24 USD. This implies a price increase of 2960% is expected in the next year compared to the current price of 0.4.
VLON Ownership
VLON Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.77 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.17 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.75 | 296.105B | ||
| PFE | PFIZER INC | 9.17 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.24 | 124.384B | ||
| ZTS | ZOETIS INC | 19.06 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.93 | 26.184B | ||
| VTRS | VIATRIS INC | 5.95 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.17 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 201.19 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VLON
Company Profile
Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-10. The firm is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company’s lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company’s second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.
Company Info
VALLON PHARMACEUTICALS INC
Two Logan Square, 100 N. 18Th Street, Suite 300
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: David Baker
Employees: 2
Phone: 12676078255.0
VALLON PHARMACEUTICALS INC / VLON FAQ
What does VLON do?
Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-10. The firm is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company’s lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company’s second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.
What is the current price of VLON stock?
The current stock price of VLON is 0.4 USD. The price decreased by -13.04% in the last trading session.
What is the dividend status of VALLON PHARMACEUTICALS INC?
VLON does not pay a dividend.
What is the ChartMill rating of VALLON PHARMACEUTICALS INC stock?
VLON has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is VLON stock listed?
VLON stock is listed on the Nasdaq exchange.
When does VALLON PHARMACEUTICALS INC (VLON) report earnings?
VALLON PHARMACEUTICALS INC (VLON) will report earnings on 2023-05-08, before the market open.
What is the ownership structure of VALLON PHARMACEUTICALS INC (VLON)?
You can find the ownership structure of VALLON PHARMACEUTICALS INC (VLON) on the Ownership tab.